Trials Offered by a Specific Doctor
Kevin Kalinsky, M.D., M.S. is an Assistant Professor of Medicine at the NewYork-Presbyterian Hospital/Columbia University Medical Center. Kalinsky received his undergraduate B.A. from Emory University. He received his M.D. from the Medical University of South Carolina and completed his Internal Medicine internship and residency and Hemathology/Oncology fellowship at Tufts Medical Center. In Boston, he also trained as a breast cancer clinical research fellow at Massachusetts General Hospital. In addition, he completed an advanced oncology fellowship in breast cancer at Memorial Sloan-Kettering Cancer Center. Since joining as a faculty member, Dr. Kalinsky completed a Master's program in Biostatistics, Patient-Oriented Research.
Dr. Kalinsky cares for patients diagnosed with breast cancer and teaches on the Breast Oncology service. Dr. Kalinsky's research involves the development of early phase clinical trials to assess novel therapeutic agents in breast cancer based on tumor genomics. The goal of his research is to translate findings developed at the bench to clinical trials for study at the bedside. His work is funded by a number of sources, including the National Institute of Health and SWOG/Hope Foundation.
|More Info||Title||Sponsor||IRB Number|
|Details||A study for patients with Epithelial Cancer using study drug IMMU-132||Immunomedics, Inc||AAAP0469|
|Details||A study for patients with metastatic breast cancer using study drug Ricolinostat in combination with nab-paclitaxel||Acetylon||AAAQ3709|
|Details||A study for patients with HER2 negative breast cancer using study drug ribociclib plus fulvestrant||Novartis||AAAP9506|
|Details||A study for women with breast cancer using a microfluidic device to detect leptomenigeal metastasis (LM)||Biocept||AAAQ4761|
|Details||A study for patients with locally advanced or metastatic breast cancer using study drug GDC-0077||Genentech, Inc.||AAAR0323|
|Details||A study for patients with LIV-1-positive metastatic breast cancer using study drug SGN-LIV1A||Seattle Genetics, Inc||AAAQ9893|
|Details||A study for post menopausal women with locally advanced or metastatic breast cancer using study drug GDC-0077||Genentech, Inc.||AAAR0323|